Stryker D&A increased by 10.1% to $120.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.1%, from $109.00M to $120.00M. Over 3 years (FY 2021 to FY 2024), D&A shows relatively stable performance with a 0.2% CAGR.
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
cf_depreciation_and_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $149.00M | $144.00M | $145.00M | $150.00M | $160.00M | $159.00M | $158.00M | $161.00M | $161.00M | $164.00M | $149.00M | $107.00M | $103.00M | $109.00M | $304.00M | $105.00M | $109.00M | $120.00M |
| QoQ Change | — | -3.4% | +0.7% | +3.4% | +6.7% | -0.6% | -0.6% | +1.9% | +0.0% | +1.9% | -9.1% | -28.2% | -3.7% | +5.8% | +178.9% | -65.5% | +3.8% | +10.1% |
| YoY Change | — | — | — | — | +7.4% | +10.4% | +9.0% | +7.3% | +0.6% | +3.1% | -5.7% | -33.5% | -36.0% | -33.5% | +104.0% | -1.9% | +5.8% | +10.1% |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $54.00M | $56.00M | $60.00M | $38.00M | $57.00M | $58.00M | $56.00M | $66.00M |
| Total | $107.00M | $103.00M | $109.00M | $304.00M | $105.00M | $109.00M | $120.00M | — |
Orthopaedics and Spine is derived from annual filings.
Orthopaedics and Spine was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.